INTRODUCTION
seizure, epilepsy, Epilepsy, idiopathic generalized, neurological illness, EGTCS
IDIOPATHIC GENERALIZED EPILEPSY, EPILEPSY, EPILEPSY
Epilepsy is a prevalent neurological illness that affects approximately 50 million individuals worldwide, with a frequency of 0.5%–1% (Fisher et al., There was a diurnal divergence in the prevalence of epilepsy in human and animal research, suggesting the function of a time‐dependent biologic signal, and it appears that melatonin oscillations can impact this fact (Novakova et al., Melatonin's anticonvulsant action has been linked to some different pathways. Its antioxidant, antiexcitotoxic, and free radical scavenging activities in the central nervous system (CNS) provide neuroprotection (Goldberg‐Stern et al., In generalized tonic‐clonic epilepsy, there have been no randomized controlled trials to test the benefit of melatonin adjunct treatment. Considering the failure of monotherapy, unwanted side effects of polytherapy, and restricted number of therapeutic choices in idiopathic generalized epilepsy, the goal of this study was to determine the effectiveness of melatonin in epilepsy with idiopathic generalized tonic‐clonic seizure alone (EGTCS) treatment (Khan et al., 